May 18 Quick Takes: ChemoCentryx’s Phase II miss; plus Teva, Zai-Novocure, Lava-J&J, Sanofi, Rhythm, ViiV
ChemoCentryx therapy fails Phase II study in rare renal disorder
ChemoCentryx Inc. (NASDAQ:CCXI) and partner Vifor Fresenius Medical Care Renal Pharma said CCX140 failed to meaningfully reduce proteinuria vs. control in a Phase II study to treat sub-nephrotic patients with orphan kidney disease focal segmental glomerulosclerosis (FSGS), missing the primary endpoint of the Phase II LUMINA-1 study. Although a second Phase II study of the CCR2 inhibitor in FSGS patients with nephrotic syndrome is due to read out next half, the partners plan to end the molecule’s development.
Teva gains a second approval for Austedo ...